Bcl-2 Family Proteins: Strategies for Overcoming Chemoresistance in Cancer

Advances in Pharmacology

Volumn 41, Issue C, 1997, Pages 501-532

  Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN BCL 2;

ANIMAL; CELL DEATH; DRUG EFFECT; HUMAN; LYMPHOMA; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; HUMANS; LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0030634474     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)61070-4     Document Type: Article

References (190)

1. Eastman A. Apoptosis: A product of programmed and unprogrammed cell death. Toxicol. Appl. Pharmacol. 121 (1993) 160-164
2. Reed J.C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol 124 (1994) 1-6
3. Reed J.C. Bcl-2 family proteins: Regulators of chemoresistance in cancer. Toxicol. Lett. 82/83 (1995) 155-158
4. Reed J.C. Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol. 7 (1995) 541-546
5. Patel T., Gores G.J., and Kaufmann S.H. The role of proteases during apoptosis. FASEB J. 10 (1996) 587-597
6. Horvitz H.R., Shaham S., and Hengartner M.O. The genetics of programmed cell death in the nematode Caenorhabditis elegans. Cold Spring Harbor Symp. Quant. Biol. 59 (1994) 377-385
7. Hengartner M.O., Ellis R.E., and Horvitz H.R. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 356 (1992) 494-499
8. Hengartner M.O., and Horvitz H.R. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammlian proto-oncogene bcl-2. Cell 76 (1994) 665-676 Feb 25
9. Tsujimoto Y., Cossman J., Jaffe E., and Croce C. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228 (1985) 1440-1443
10. Tsujimoto Y., and Croce C.M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. USA 83 (1986) 5214-5218
11. Vaux D.L., Cory S., and Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335 (1988) 440-442
12. Hockenbery D.M., Nunez G., Milliman C., Schreiber R.D., and Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 (1990) 334-336
13. Reed J., Stein C., Haldar S., Subasinghe C., Croce C., Yum S., and Cohen J. Antisense-mediated inhibition of bcl-2 proto-oncogene expression and leukemic cell growth: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 50 (1990) 6565-6570
14. Reed J., Haldar S., Cuddy M., Croce C., and Makover D. Bcl-2-mediated tumorigenicity in a T-lymphoid cell line: Synergy with C-MYC and inhibition by Bcl-2 antisense. Proc. Natl. Acad. Sci. USA 87 (1990) 3660-3664
15. McDonnell T.J., Deane N., Platt F.M., Numez G., Jaeger V., McKearn J.P., and Korsmeyer S.J. bcl-2-immunoglobulin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation. Cell 57 (1989) 79-88
16. Katsumata M., Siegel R., Louie D., Miyashita T., Tanaka S., Greene M., and Reed J.C. Differential effects of bcl-2 on B- and T-lymphocytes in transgenic mice. Proc. Natl. Acad. Sci. USA 89 (1992) 11376-11380
17. McDonnell T.J., Nunez G., Platt F.M., Hockenberry D., London L., McKearn J.P., and Korsmeyer S.J. Deregulated bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol. Cell. Biol. 10 (1990) 1901-1907
18. Miyashita T., and Reed J.C. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52 (1992) 5407-5411
19. Miyashita T., and Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81 (1993) 151-157
20. Walton W.I., Whysong D., O'Connor P.M., Hockenberry D., Korsmeyer S.J., and Kohn K.W. Constitutive expression of human bcl-2 modulates mitrogen mustard and camptothecin induced apoptosis. Cancer Res. 53 (1993) 1853-1861
21. Kamesaki S., Kamesaki H., Jorgensen T.J., Tanizawa A., Pommier Y., and Cossman J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res. 53 (1993) 4251-4256
22. Fisher T.C., Milner A.E., Gregory C.D., Jackman A.L., Aherne G.W., Harley J.A., Dive C., and Hickman J.A. Bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res. 53 (1993) 3321-3326
23. Tang C., Willingham M.C., Reed J.C., Miyashita T., Ray S., Ponnathpur V., Huang Y., Mahoney M.E., Bullock G., and Bhalla K. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8 (1994) 1960-1969
24. Minn A.J., Rudin C.M., Boise L.H., and Thompson C.B. Expression of Bcl-XL can confer a multidrug resistance phenotype. Blood 86 (1995) 1903-1910
25. Ibrado A.M., Huang Y., Fang G., and Bhalla K. Bcl-xL overexpression inhibits taxol-induced yama protease activity and apoptosis. Cell Growth Differ. 7 (1996) 1087-1094
26. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
27. Vaux D.L., and Strasser A. The molecular biology of apoptosis. Proc. Natl. Acad. Sci. USA 93 (1996) 2239-2244
28. Kitada S., Takayama S., DeRiel K., Tanaka S., and Reed J.C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev. 4 (1994) 71-79
29. Campos L., Sabido O., Rouault J.-P., and Guyotat D. Effects of Bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84 (1994) 595-600
30. Berchem G.J., Bosseler M., Sugars L.Y., Voeller H.J., Zeitlin S., and Gelmann E.P. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 55 (1995) 735-738
31. Teixeira C., Reed J.C., and Pratt M.A.C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 protooncogene expression in human breast cancer cells. Cancer Res. 55 (1995) 3902-3907
32. Bargou R.C., Wagener C., Bommert K., Mapara M.Y., Daniel P.T., Arnold W., Dietel M., Guski H., Feller A., Royer H.D., and Dorken B. Overexpression of the death-promoting gene bax-ã which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J. Clin. Invest. 97 (1996) 2651-2659 June 1
33. Sumantran V.N., Ealovega M.W., Nuñez G., Clarke M.F., and Wicha M.S. Overexpression of Bcl-XS sentizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res. 55 (1995) 2507-2510
34. Reed J.C. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol./Oncol. Clin. North Am. 9 (1995) 451-474
35. McDonnell T., Troncoso T., Brisbary P., Logothetis C., Chung L., Hsieh J., Tu S., and Campbell M. Expression of the protooncogene BCL-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52 (1992) 6940-6944
36. Furuya Y., Krajewski S., Epstein J.I., Reed J.C., and Isaacs J.T. Enhanced expression of Bcl-2 and the progression of human and rodent prostatic cancers. Clin. Cancer Res. 2 (1996) 389-398
37. Colombel M., Symmans F., Gil S., O'Toole K.M., Chopin D., Benson M., Olsson C.A., Korsmeyer S., and Buttyan R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143 (1993) 390-400
38. Hague A., Moorghen M., Hicks D., Chapman M., and Paraskeva C. Bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene 9 (1994) 3367-3370
39. Bedi A., Pasricha P.J., Akhtar A.J., Barber J.P., Bedi G.C., Giardiello F.M., Zehnbauer B.A., Hamilton S.R., and Jones R.J. Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 55 (1995) 1811-1816
40. Krajewska M., Moss S., Krajewski S., Song K., Holt P., and Reed J.C. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res. 56 (1996) 2422-2427
41. Flohil C.C., Janssen P.A., and Bosman F.T. Expression of bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. J. Pathol. 178 (1996) 393-397
42. Bronner M., Culin C., Reed J.C., and Furth E.E. Bcl-2-proto-oncogene and the gastrointestinal epithelial tumor progression model. Am. J. Pathol. 146 (1995) 20-26
43. Ben-Ezra J.M., Kornstein M.J., Grimes M.M., and Krystal G. Small cell carcinomas of the lung express the bcl-2 protein. Am. J. Pathol. 145 (1994) 1036-1040
44. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi M., Angeletti C.A., Basolo F., and Bevilacqua G. Bcl-2 protein: A prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br. J. Cancer 71 (1995) 1003-1007
45. Jiang S.-X., Sato Y., Kuwao S., and Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J. Pathol. 177 (1995) 135-138
46. Pezzella F., Turley H., Kuzu I., Tungekar M.F., Dunnill M.S., Pierce C.B., Harris A., Gatter K.C., and Mason D.Y. bcl-2 protein in non-small-celllung carcinoma. N. Engl. J. Med. 329 (1993) 690-694
47. Chandler D., El-Naggar A.K., Brisbay S., Redline R.W., and McDonnell T.J. Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: Evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum. Pathol. 25 (1994) 789-796
48. Krajewski S., Chatten J., Hanada M., Womer R., and Reed J.C. Immunohisto chemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Lab Invest. 71 (1995) 42-54
49. Castle V., Heidelberger K.P., Bromberg J., Ou X., Dole M., and Nunez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am. J. Pathol. 143 (1993) 1543-1550
50. Tron V.A., Krajewski S., Klein-Parker H., Li G., Ho V.C., and Reed J.C. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am. J. Pathol. 146 3 (1995) 643-650
51. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Hoffman B., Lieberman D., and Reed J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vivo. Oncogene 9 (1994) 1799-1805
52. Miyashita T., Harigai M., Hanada M., and Reed J.C. Identification of a p53- dependent negative response element in the bcl-2 gene. Cancer Res. 54 (1994) 3131-3135
53. Hermine O., Haioun C., Lepage E., d'Agay M.-F., Briere J., Lavignac C., Fillet G., Salles G., Marolleau J.-P., Diebold J., Reyes F., and Gaulard P. Prognostic significance of Bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87 (1996) 265-272
54. Hill M.E., MacLennan K.A., Cunningham D.C., Hudson B.V., Burke M., Clarke P., DiStefano F., Anderson L., Hudson G.V., Mason D., Selby P., and Linch D.C. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A british national lymphoma investigation study. Blood 88 (1996) 1046-1051 August 1
55. Campos L., Roualult J.-P., Sabido O., Roubi N., Vasselon C., Archimbaud E., Magaud J.-P., and Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81 (1993) 3091-3096
56. Maung Z.T., MacLean F.R., Reid M.M., Pearson A.D.J., Proctor S.J., Hamilton P.J., and Hall A.G. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br. J. Haematol. 88 (1994) 105-109
57. Gasparini G., Barbareschi M., Doglioni C., Palma P.D., Mauri F.A., Boracchi P., Bevilacqua P., Caffo O., Morelli L., Verderio P., Pezzella F., and Harris A.L. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node positive breast cancer. Clin. Cancer Res. 1 (1995) 189-198
58. Hellermans P., van Dam P.A., Weyler J., van Oosterom A.T., Buytaert P., and Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br. J. Cancer 72 (1995) 354-360
59. Joensuu H., Pylkkanen L., and Toikkanen S. Bcl-2 protein expression and longterm survival in breast cancer. Am, J. Pathol. 145 (1994) 1191-1198
60. Silvestrini R., Veneroni S., Daidone M.G., Benini E., Boracchi P., Mezzetti M., Di Fronzo G., Rilke F., and Veronesi U. The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. 86 (1994) 499-504
61. Silvestrini R., Benini E., Veneroni S., Daidone M.G., Tomasic G., Squicciarini P., and Salvadori B. bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. Clin. Oncol. 14 (1996) 1604-1610 May
62. Ohsaki Y., Toyoshima E., Fujiuichi S., Matsui H., Hirata S., Miyokawa N., Kubo Y., and Kikuchi K. bcl-2 and p53 protein expression in non-small cell lung cancers: Correlation with survival time. Clin. Cancer Res. 2 (1996) 915-920
63. Krajewski S., Blomvqvist C., Franssila K., Krajewska M., Wasenius V.-M., Niskanen E., and Reed J.C. Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 5 (1995) 4471-4478
64. Aguilar-Santelises M., Rottenberg M.E., Lewin N., Mellstedt H., and Jondal M. Bcl-2, Bax, and p53 expression in B-cell in relation to in vitro survival and clinical progression. Int. J. Cancer 69 (1996) 114-119
65. Krajewski S., Thor A., Edgerton S., Moore D., Krajewska M., and Reed J.C. Immunohistochemical analysis of Bax and Bcl-2 in p53-immunopositive breast cancers. Clin. Cancer Res. 3 (1996) 199-208
66. Reed J.C. Balancing cell life and death: Bax, apoptosis, and breast cancer. J. Clin. Invest. 97 (1996) 2403-2404
67. Bargou R.C., Daniel P.T., Mapara M.Y., Bommert K., Wagenert K., Wagener C., Kallinich B., Royer H.D., and Dorken B. Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-a expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer 60 (1995) 854-859
68. Wagener C., Bargou R.C., Daniel P.T., Bommert K., Mapara M.Y., Royer H.D., and Dorken B. Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int. J. Cancer 67 1 (1996) 138-141
69. Kitada S., Krajewski S., Miyashita T., Krajewska M., and Reed J.C. Gammaradiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. Oncogene 12 (1996) 187-192
70. Miyashita T., and Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell 80 (1995) 293-299
71. Krajewska M., Fenoglio-Preiser C.M., Krajewski S., Song K., Macdonald J.S., Stemmerman G., and Reed J.C. lmmunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am. J. Pathol. 149 5 (1996) 1449-1457
72. Krajewski M., Krajewski S., Epstein J.I., Shavaik A., Sauvageot J., Song K., Kitada S., and Reed J.C. lmmunohistochemical analysis of bcl-2, bax, bcl-X, and mcl1 expression in prostate cancers. Am. J. Pathol. 148 (1996) 1567-1576
73. Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., Mao X., Nunez G., and Thompson C.B. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74 (1993) 597-608
74. Oltvai Z., Milliman C., and Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (1993) 609-619
75. Kozopas K.M., Yang T., Buchan H.L., Zhou P., and Craig R. Mcl-1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to bcl-2. Proc. Natl. Acad. Sci. USA 90 (1993) 3516-3520
76. Lin E.Y., Orlofsky A., Berger M.S., and Prystowsky M.C. Characterization of Al, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J. Immunol. 151 (1993) 1979-1988
77. Gibson L., Holmgreen S., Huang P.D.C.S., Bernard O., Copeland N.G., Jenkins N.A., Sutherland G.R., Baker E., Adams J.M., and Cory S. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 13 (1996) 665-675
78. Gillet G., Guerin M., Trembleau A., and Brun G. A Bcl-2-related gene is activated in avian cells transformed by the Rous sarcoma virus. EMBOJ. 14 (1995) 1372-1381
79. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., and Korsmeyer S.J. Bad: A heterodimeric partner for Bcl-XL and Bcl-2, displaces bax and promotes cell death. cell 80 (1995) 285-291
80. Chittenden T., Harrington E.A., O'Connor R., Flemington C., Lutz R.J., Evan G.I., and Guild B.C. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374 (1995) 733-736
81. Kiefer M.C., Brauer M.J., Powers V.C., Wu J.J., Ubansky S.R., Tomei L.D., and Barr P.J. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 374 (1995) 736-739
82. Choi S.S., Park I.-C., Yun J.W., Sung Y.C., Hong S., and Shin H. A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 11 (1995) 1693-1698
83. Farrow S.N., White J.H.M., Martinou I., Raven T., Pun K.-T., Grinham C.J., Martinou J.-C., and Brown R. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 374 (1995) 731-733
84. Boyd J.M., Gallo G.J., Elangovan B., Houghton A.B., Malstrom S., Avery B.J., Ebb R.G., Subramanian T., Chittenden T., Lutz R.J., and Chinnadurai G. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11 (1995) 1921-1928
85. Wang K., Yin W.-M., Chao D.T., Milliman C.L., and Korsmeyer S.J. BID: A novel BH3 domain-only death agonist. Genes Dev. 10 (1996) 2859-2869
86. Das R., Reddy E.P., Chatterjee D., and Adrews D.W. Identification of a novel Bcl-2 related gene, BRAG-1, in human glioma. Oncogene 12 (1996) 947-951
87. Cruz-Reyes J., and Tata J.R. Cloning, characterization and expression of two Xenopus bcl-2-like cell-survival genes. Gene 158 (1995) 171-179
88. Rao L., Debbas M., Sabbatini P., Hockenberry D., Korsmeyer S., and White E. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and bcl-2 proteins. Proc. Natl. Acad. Sci. USA 89 (1992) 7742-7746
89. Henderson S., Huen D., Rowe M., Dawson C., Johnson G., and Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc. Natl. Acad. Sci. USA 90 (1993) 8479-8483
90. Neilan J.G., Lu Z., Afonso C.L., Kutish G.F., Sussman M.D., and Rock D.L. An African swine fever virus gene with similarity to the proto-oncogene bcl-2 and the Epstein-Barr virus gene BHRF1. J. Virol. 67 (1993) 4391-4394
91. Smith C.A. A novel viral homologue of Bcl-2 and Ced-9. Trends Cell Biol. 5 (1995) 344
92. Zha H., Aime-Sempe C., Sato T., and Reed J.C. Pro-apoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J. Biol. Chem. 271 (1996) 7440-7444
93. Wang H.-G., Rapp U.R., and Reed J.C. Bcl-2 targets the protein kinase Raf- 1 to mitochondria. Cell 87 (1996) 629-638
94. Hunter J.J., Bond B.L., and Parslow T.G. Functional dissection of the human Bcl-2 protein: Sequence requirements for inhibition of apoptosis. Mol. Cell. Biol. 16 (1996) 877-883
95. Borner C., Martinou I., Mattmann C., Irmler M., Scharer E., Martinou J.-C., and Tschopp J. The protein bcl-2 alpha does not require membrane attachment, but two conserved domains to suppress apoptosis. J. Cell Biol. 126 (1994) 1059-1068
96. Chittenden T., Flemington C., Houghton A.B., Ebb R.G., Gallo G.J., Elangovan B., Chinnadurai G., and Lutz R.J. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 14 (1995) 5589-5596
97. Han J., Sabbatini P., Perez D., Rao L., Modha D., and White E. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev. 10 (1996) 461-477
98. Hunter J.J., and Parslow T.G. A peptide sequence from Bax that converts Bcl- 2 into an activator of apoptosis. J. Biol. Chem. 271 (1996) 8521-8524
99. Sato T., Irie S., Krajewski S., and Reed J.C. Cloning and sequencing of cDNA encoding rat bcl-2 protein. Gene 140 (1994) 291-292
100. Sedlak T.W., Oltvai Z.N., Yang E., Wang K., Boise L.H., Thompson C.B., and Korsmeyer S.J. Multiple Bcl-2 family members demonstrate selective dimeriza-tions with Bax. Proc. Natl. Acad. Sci. USA 92 (1995) 7834-7838
101. Zha H., Fisk H.A., Yaffe M.P., Mahajan N., Herman B., and Reed J.C. Structure-function comparisons of the proapoptotic protein bax in yeast and mammalian cells. Mol. Cell. Biol. 16 11 (1996) 6494-6508
102. Yin X.M., Oltvai Z.N., and Korsmeyer S.J. BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 369 (1994) 321-333
103. Hanada M., Aimé-Sempé C., Sato T., and Reed J.C. Structure-function analysis of bcl-2 protein: Identification of conserved domains important for homodimerization with bcl-2 and heterodimerization with bax. J. Biol. Chem. 270 (1995) 11962-11968
104. Badley A.D., McElhinny J.A., Leibson P.J., Lynch D.H., Alderson M.R., and Paya C.V. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J. Virol. 70 (1996) 199-206
105. Bodrug S.E., Aime-Sempe C., Sato T., Krajewski S., Hanada M., and Reed J.C. Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: Evidence for a novel mechanism of regulating Bcl-2 family protein function. Cell Death Differ. 2 (1995) 173-182
106. Cheng E.H.-Y., Levine B., Boise L.H., Thompson C.B., and Hardwick J.M. Bax-independent inhibition of apoptosis by Bcl-XL. Nature 379 (1996) 554-556
107. Sato T., Hanada M., Bodrug S., Irie S., Iwama N., Boise L.H., Thompson C.B., Golemis E., Fong L., Wang H.-G., and Reed J.C. Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system. Proc. Natl. Acad. Sci. USA 91 (1994) 9238-9242
108. Minn A.J., Boise L.H., and Thompson C.B. Bcl-XS antagonizes the protective effects of Bcl-XL. J. Biol. Chem. 271 (1996) 6306-6312
109. Zha J., Harada H., Yang E., Jockel J., and Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 87 (1996) 619-628
110. Krajewski S., Tanaka S., Takayama S., Schibler M.J., Fenton W., and Reed J.C. Investigations of the subcellular distribution of the bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 53 (1993) 4701-4714
111. Lithgow T., van Driel R., Bertram J.F., and Strasser A. The protein product of the oncogene bcl-2 is a component membrane. Cell Growth Differ. 3 (1994) 411-417
112. Yang T., Kozopas K.M., and Craig R.W. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J. Cell Biol. 128 (1995) 1173-1184
113. White E., and Cipriani R. Specific disruption of intermediate filaments and the nuclear lamina by the 19-kDa product of the adenovirus E1B oncogene. Proc. Natl. Acad. Sci. USA 86 (1989) 9886-9890
114. Kane D.J., Sarafin T.A., Auton S., Hahn H., Gralla F.B., Valentine J.C., Ord T., and Bredesen D.E. Bcl-2 inhibition of neural cell death: Decreased generation of reactive oxygen species. Science 262 (1993) 1274-1276
115. Hockenbery D., Oltvai Z., Yin X.-M., Milliman C., and Korsmeyer S.J. Bcl- 2 functions in an antioxidant pathway to prevent apoptosis. Cell 75 (1993) 241-251
116. Shimizu S., Eguchi Y., Kosaka H., Kamiike W., Matsuda H., and Tsujimoto Y. Prevention of hypoxia-induced cell death by Bcl-2 and BclxL. Nature 374 (1995) 811-813
117. Jacobson M.D., and Raff M.C. Programmed cell death and Bcl-2 protection in very low oxygen. Nature 374 (1995) 814-816
118. 2+ pool depletion. Oncogene 12 (1996) 814-816
119. Baffy G., Miyashita T., Williamson J.R., and Reed J.C. Apoptosis induced by withdrawal of interleukin-3 [IL-3] from an IL-3-dependent hematopoietic cell line associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J. Biol. Chem. 268 (1993) 6511-6519
120. 2+ fluxes. Proc. Natl. Acad. Sci. USA 91 (1994) 6569-6573
121. Murphy A.N., Bredesen D.E., Cotopassi G., Wang E., and Fiskum G. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Neurobiology 93 (1996) 9893-9898
122. 2++. Oncogene 12 (1996) 2259-2266
123. Ryan J.J., orochownik E., Gottlieb C.A., Apel I.J., Merion R., Nuñez G., and Clarke M.F. c-myc and bcl-2 modulates p53 function by altering p53 subcellular trafficking during the cell cycle. Proc. Natl. Acad. Sci. USA 91 (1994) 5878-5882
124. Meikrantz W., Gisselbrecht S., Tam S.W., and Schlegel R. Activation of cyclin A-dependent protein kinases during apoptosis. Proc. Natl. Acad. Sci. USA 91 (1994) 3754-3758
125. Hengartner M.O., and Horvitz H.R. Programmed cell death in Caenorhabditis elegans. Curr. Opin. Genet. Dev. 4 (1994) 581-586 August
126. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., and Yuan J. Human ICE/CED-3 protease nomenclature. Cell 87 (1996) 171
127. Boulakia C.A., Chen G., Ng F.W.H., Teodoro J.G., Branton P.E., Nicholson D.W., Poirier G.G., and Shore G.C. Bcl-2 and adenovirus E1B 19 kDa protein prevent ElA-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase. Oncogene 12 (1996) 29-36
128. Monney L., Otter I., Olivier R., Ravn U., Mirzasaleh H., Fellay I., Poirier G.G., and Borner C. Bcl-2 overexpression blocks activation of the death protease CPP32/Yama/Apopain. Biochem. Biophys. Res. Commun. 221 (1996) 340-345
129. Srinivasan A., Foster L.M., Testa M.-P., Ord T., Keane R.W., Bredesen D.E., and Kayalar C. Bcl-2 expression in neural cells blocks activation of ice/ced-3 family proteases during apoptosis. J. Neurosci. 16 (1996) 5654-5660
130. Ibrado A.M., Huang Y., Fang G., Liu L., and Bhalla K. Overexpression of Bcl-2 or Bcl-xl inhibits Ara-C-induced Cpp32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res. 56 (1996) 4743-4748
131. Smyth M.J., Perry D.K., Zhang J., Poirier G.G., Hannun Y.A., and Obeid L.M. prICE: A downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2. Biochem. J. 316 (1996) 25-28
132. Mebmer U.K., Reimer D.M., Reed J.C., and Brune B. Nitric oxide induced poly(ADP-ribose) polymerase cleavage in RAW 264.7 macrophage apoptosis is blocked by Bcl-2. FEBS Lett. 384 (1996) 162-166
133. Wang H.-G., Miyashita T., Takayama S., Sato T., Torigoe T., Krajewski S., Tanaka S., Hovey I.L., Toppmair J., Rapp U.R., and Reed J.C. Apoptosis regulation by interaction of bcl-2 protein and Raf-1 kinase. Oncogene 9 (1994) 2751-2756
134. Wang H.-G., Millan J.A., Cox A.D., Der C.J., Rapp U.R., Beck T., Zha H., and Reed J.C. R-ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism. J. Cell Biol. 129 (1995) 1103-1114
135. Fernandez-Sarbia M.J., and Bischoff J.R. Bcl-2 associates with the ras-related protein R-ras p23. Nature 366 (1993) 274-275
136. Bernardi P., Broekemeier K.M., and Pfeiffer D.R. Recent progress on regulation of the mitochondrial permeability transition pore; A cyclosporin-sensitive pore in the inner mitochondrial membrane. J. Bioenergetics Biomembr. 26 (1994) 509-517
137. de Jong D., Prins F.A., Mason D.Y., Reed J.C., Ommen G.B., and Kluin P.M. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res. 54 (1994) 256-260
138. Nicolli A., Basso E., Petronilli V., Wenger R.M., and Bernardi P. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, a cyclosporin A-sensitive channel. J. Biol. Chem. 271 (1996) 2185-2192
139. 2++-requiring, cyclosporin-sensitive pathway. Biochem. Biophys. Res. Commun. 161 (1989) 619-625
140. Zamzami N., Susin S.A., Marchetti P., Hirsch T., Gomez-Monterrey I., Castedo M., and Kroemer G. Mitochondrial control of nuclear apoptosis. J. Exp. Med. 183 (1996) 1533-1544
141. Liu X., Kim C.N., Yang J., Jemmerson R., and Wang X. Induction of apoptotic program in cell-free extracts: Requirements for dATP and Cytochrome C. Cell 86 (1996) 147-157 (July 12)
142. Susin S.A., Zamzami N., Castedo M., Hirsch T., Marchetti P., Macho A., Daugas E., Geuskens M., and Kroemer G. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J. Exp. Med. 184 4 (1996) 1331-1342
143. Zamzami N., Marchetti P., Castedo M., Hirsch T., Susin S.A., Masse B., and Kroemer G. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett. 384 (1996) 53-57
144. Marchetti P., Hirsch T., Zamzami N., Castedo M., Decaudin D., Susin S.A., Masse B., and Kroemer G. Mitochondrial permeability transition triggers lymphocyte apoptosis. J. Immunol. 157 (1996) 4830-4836
145. Muchmore S.W., Sattler M., Liang H., Meadows R.P., Harlan J.E., Yoon H.S., Nettesheim D., Changs B.S., Thompson C.B., Wong S., Ng S., and Fesik S.W. X-ray and NMR structure of human Bcl-XL, an inhibitor of programmed cell death. Nature 381 (1996) 335-341
146. Zhu W., Cowie A., Wasfy L., Leber B., and Andrews D. Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. EMBO J. 15 16 (1996) 4130-4141
147. Shimizu S., Eguchi Y., Kamiike W., Waguri S., Uchiyama Y., Matsuda H., and Tsujimoto Y. Retardation of chemical hypoxia-induced necrotic cell death by Bcl-2 and ICE inhibitors: Possible involvement of common mediators in apoptotic and necrotic signal transductions. Oncogene 12 (1996) 2045-2050
148. Shimizu S., Eguchi Y., Kamiike W., Itoh Y., Hasegawa J., Yamabe K., Otsuki Y., Matsuda H., and Tsujimoto Y. Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by bcl-2 and bcl-XL. Cancer Res. 56 (1996) 2161-2166
149. Kane D.J., Örd T., Anton R., and Bredesen D.E. Expression of Bcl-2 inhibits necrotic neural cell death. J. Neurosci. Res. 40 (1995) 269-275
150. Jacobson M.D., Burne J.F., King M.P., Miyashita T., Reed J.C., and Raff M.C. Apoptosis and bcl-2 protein in cells without mitochondrial DNA. Nature 361 (1993) 365-368
151. Marchetti P., Susin S.A., Decaudin D., Gamen S., Castedo M., Hirsch T., Zamzami N., Naval J., Senik A., and Kroemer G. Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res. 56 (1996) 2033-2038
152. Parker M.W., Postma J.P.M., Pattus F., Tucker A.D., and Tsernoglou D. Structure of the pore-forming domain of colicin A at 24 Å resolution. J. Mol. Biol. 224 (1992) 639-657
153. Duche D., Izard J., Gonzales-Manas J.M., Parkers M.W., Crest M., Chartier M., and Baty D. Membrane topology of the colicin a pore-forming domain analyzed by disulfide bone engineering. J. Biol. Chem. 271 (1996) 15401-15406
154. Merrill A.R., Cohen F.S., and Cramer W.A. On the nature of the structural change of the colicin El channel peptide necessary for its translocation-competent state. Biochemistry 29 (1990) 5829-5836
155. Cramer W.A., Zhang Y.-L., Schendel S., Merrill A.R., Song H.Y., Stauffacher C.V., and Cohen F.S. Dynamic properties of the colicin El ion channel. FEMS Microbiol. Immunol. 105 (1992) 71-82
156. Shin Y.-K., Levinthal C., Levinthal F., and Hubbell W.L. Colicin El binding to membranes: Time-resolved studies of spin-labeled mutants. Science 259 (1993)
157. Donovan J.J., Simon M.I., Draper R.K., and Montal M. Diphtheria toxin forms transmembrane channels in planar lipid bilayers. Proc. Natl. Acad. Sci. USA 78 (1981) 172-176
158. Konisky J. Colicins and other bacteriocins with established modes of action. Annu. Rev. Microbiol. 36 (1982) 125-144
159. Middleton G., Nunez G., and Davies A.M. Bax promotes neuronal survival and antagonises the survival effects of neurotropic factors. Development 122 (1996) 695-701
160. Chen C.-Y., and Faller D.V. Phosphorylation of Bcl-2 protein and association with p21Ras in Ras-induced apoptosis. J. Biol. Chem. 271 (1996) 2376-2379
161. Naumovski L., and Cleary M.L. The p53-binding protein 53BP2 also interacts with Bcl-2 and impedes cell cycle progression at G2/M. Mol. Cell. Biol. 16 (1996) 3884-3892
162. Kurschner C., and Morgan J.I. The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system. Mol. Brain Res. 30 (1995) 165-168
163. Takayama S., Sato T., Krajewski S., Kochel K., Irie S., Millan J.A., and Reed J.C. Cloning and functional analysis of BAG-1: A novel Bcl-2 binding protein with anti-cell death activity. Cell 80 (1995) 279-284
164. Boyd J.M., Malstrom S., Subramanian T., Venkatesch L.K., Schaeper U., Elangovan B., D'Sa-Epper C., and Chinnadurai G. Adenovirus E1B 19 kDa and bcl-2 proteins interact with a common set of cellular proteins. Cell 79 (1993) 341-351
165. Wang H.-G., Takayama S., Rapp U.R., and Reed J.C. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc. Natl. Acad. Sci. USA 93 (1996) 7063-7068 (July)
166. Chang B.S., Minn A.J., Muchmore S.W., Fesik S.W., and Thompson C.B. EMBO J. (1996) in press
167. Haldar S., Chintapalli J., and Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56 (1996) 1253-1255
168. Blagosklonny M., Schulte T., Nguyen P., Trepel J., and Neckers L. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 transduction pathway. Cancer Res. 56 (1996) 1851-1854
169. Blagosklonny M.V., Schulte T.W., Nguyen P., Mimnaugh E.G., Trepel J., and Neckers L. Taxol induction of p21WAF12 and p53 requires c-raf-1. Cancer Res. 55 (1995) 4623-4626
170. Aimé-Sempé C., Kitada S., and Reed J.C. Investigators of Taxol-mediated phosphorylation of bcl-2. Blood 88 10 (1996) 106
171. Tanaka S., Louie D.C., Kant J.A., and Reed J.C. Frequent somatic mutations in translocated BCL2 genes of non-Hodgkin's lymphomas patients. Blood 79 (1992) 229
172. Matolcsy A., Casali P., Warnke R.A., and Knowles D.M. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translo cated Bcl-2-gene. Blood 88 10 (1996) 3937-3944
173. Reed J.C., and Tanaska S.T. Somatic point mutations in translocated bcl-2 alleles of non-Hodgkin's lymphomas and lymphocytic leukemias: Implications for mechanisms of tumor progression. Leuk. Lymphoma 10 (1993) 157-163
174. Pietenpol J.A., Papadopoulos N., Markowitz S., Willson K.V., Kinzler K.W., and Vogelstein B. Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res. 54 (1994) 3714-3717
175. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J. Biol. Chem. 271 (1996) 12695-12698
176. Mazel S., Burtrum D., and Petrie H.T. Regulation of cell division cycle progression by bcl-2 expression: A potential mechanism for inhibition of programmed cell death. J. Exp. Med. 183 (1996) 2219-2226
177. Linette G.P., Li Y., Roth K., and Korsmeyer S.J. Cross talk between cell death and cell cycle progression. BCL-2 regulates NFAT-medicated activation. Proc. Natl. Acad. Sci. USA 93 (1996) 9545-9552
178. May W.S., Tyler P.G., Ito T., Armstrong D.K., Qatsha K.A., and Davidson N.E. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of Bcl-2 alpha in association with suppression of apoptosis. J. Biol. Chem. 269 (1994) 26865-26870
179. Grimm S., Bauer M.K.A., Baeuerle P., and Schulze-Osthoff K. Bcl-2 down-regulates the activity of transcription factor NE-kB induced apoptosis. J. Cell Biol. 134 (1996) 13-23 July
180. Reed J.C., Talwar H.S., Rapp U.R., Cuddy M., and Fisher G.T. Mitochon drial protein p26 bcl-2 reduces growth factor requirements of NIH3T3 fibroblasts. Exp. Cell Res. 195 (1991) 277-283
181. Miyazaki T., Liu Z.-J., Kawahara A., Minami Y., Yamada K., Tsujimoto Y., Barsou mian E.L., Perlmutter R.M., and Taniguchi T. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 81 (1995) 223-231
182. Bissonnette R.P., Echeverri F., Mahboubi A., and Green D.R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359 (1992) 552-554
183. Fanidi A., Harrington E.A., and Evan G.I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359 (1992) 554-556
184. Kranenburg O., van der Eb A.J., and Zantema A. Cyclin Dl is an essential mediator of apoptotic neuronal cell death. EMBO J. 15 (1996) 46-54
185. Raff M.C., Barres B.A., Burne J.F., Coles H.S., Ishizaki Y., and Jacobson M.D. Programmed cell death and the control of cell survival: Lessons from the nervous system. Science 262 (1993) 695-700 (October 29)
186. Frisch S.M., and Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124 (1994) 619-626
187. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., and Perucho M. Frequent framshift somatic mutations in the pro-apoptotic gene bax in colon cancer of the microsatellite mutator phenotype. Science 275 (1997) 967-969
188. Elledge S.J. Cell cycle checkpoints: Preventing an identity crisis. Science 274 (1996) 1664-1667
189. Minn A.J., Velez P., Schondel S.L., Liang H., Muchmore S.W., Fesik S.W., Fill M., and Thompson C.B. Bcl-Xc forms an ion channel in synthetic lipid mem branes. Nature 385 (1997) 353-357
190. S.L. Schendel, Z. Xie, M.O. Montal, S. Matsuyama, S. Montal J.C. Reed. Channel formation by anti-apoptotic protein, Bcl-2 Proc. Natl. Acad. Sci. USA in press